Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

All A·Important B·Normal #weight loss pills ✕
B
On September 30, Eli Lilly announced the research data of Eloratzp (a combination therapy of Eloralintide and Tilpotide). The results showed that the combination therapy was more effective than tilpotide 15 mg monotherapy in terms of weight loss and glycated hemoglobin (A1C) reduction. Eli Lilly's amyloid peptide drug combination achieved a 23% weight loss effect in the study.
#weight loss pills09-30 22:17
B
On September 30th, AbbVie announced that its drug under development, ABBV-295, showed a weight loss effect of up to 9.8% in a phase 1 clinical trial, showing "meaningful weight loss."
#clinical trial#weight loss pills09-30 17:52
B
September 23rd, Novo Nordisk is reported to be considering upgrading its New York listing arrangement to enhance the Danish weight loss drug giant's brand influence and market recognition in the US market.
#Futures Market Intelligence#weight loss pills#Novo Nordisk09-23 12:03
B
On September 21, Novo Nordisk stated that Mexico is the next market for Wegovy oral drugs.
#Novo Nordisk#weight loss pills09-21 20:59
B
On September 21, the head of Novo Nordisk in the United States said that since January, Novo Nordisk’s market share in the field of obesity has increased by about 8 percentage points.
#Novo Nordisk#weight loss pills09-21 20:19
B
On September 21, the CEO of Novo Nordisk stated that it would launch new innovative drugs for diabetes and obesity before losing its exclusive patent rights.
#Innovative drugs#Novo Nordisk#weight loss pills09-21 16:32
B
On September 21, Novo Nordisk’s CEO stated that by 2030, the company’s production capacity will be able to meet the needs of 5 million patients using Wegovy oral medicine.
#Novo Nordisk#weight loss pills09-21 16:28
B
September 20th: Novo Nordisk will hold an investor day event next Monday and update its company strategy. Institutional shareholders urge it to develop new drugs, promote mergers and acquisitions, and reduce its reliance on weight loss drugs to cope with competition from Eli Lilly.
#weight loss pills#Novo Nordisk09-20 17:50
B
On September 15th, Eli Lilly stated that its oral weight loss drug Foundayo has accounted for more than 30% of new patients in the U.S. oral obesity treatment market since its launch in the United States in April.
#weight loss pills#U.S. stock trends09-15 20:57
B
On August 31, Eli Lilly stated that the research data of two drugs, Taltz and Zepbound, in the treatment of obesity have shown positive results.
#U.S. stock trends#weight loss pills08-31 19:06